MENU
+Compare
NTLA
Stock ticker: NASDAQ
AS OF
May 13, 10:52 AM (EDT)
Price
$8.44
Change
-$0.11 (-1.29%)
Capitalization
885.64M

NTLA stock forecast, quote, news & analysis

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics... Show more

Industry: #Biotechnology
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for NTLA with price predictions
May 12, 2025

Aroon Indicator for NTLA shows an upward move is likely

NTLA's Aroon Indicator triggered a bullish signal on May 12, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 144 similar instances where the Aroon Indicator showed a similar pattern. In of the 144 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where NTLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 12, 2025. You may want to consider a long position or call options on NTLA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

NTLA moved above its 50-day moving average on May 12, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NTLA broke above its upper Bollinger Band on April 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.136) is normal, around the industry mean (14.767). P/E Ratio (0.000) is within average values for comparable stocks, (65.482). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.018). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (18.939) is also within normal values, averaging (254.233).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.15B. The market cap for tickers in the group ranges from 151 to 296.96B. NONOF holds the highest valuation in this group at 296.96B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was -8%. CTMX experienced the highest price growth at 122%, while NCNA experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 15% and the average quarterly volume growth was 68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 90
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com